-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130

Benzinga·07/16/2026 11:46:38
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $124 to $130.